Conflict of interest statements: Dr RJ Bernardo serves on the medical advisory board for
Janssen Pharmaceuticals. Dr VA de Jesus Perez has no conflict of interest to declare …

Background: Health disparities have a major impact in the quality of life and clinical care
received by minorities in the United States. Pulmonary arterial hypertension (PAH) is a rare …

The field of pulmonary hypertension (PH) has expanded dramatically during the last three
decades. International consensus statements have laid the foundation for its clinical …

Rationale: Pulmonary arterial hypertension (PAH) is a heterogeneous disease within a
complex diagnostic and treatment environment. Other complex heart and lung diseases …

Expert medical specialty care in the modern era took shape in the 19th century, according to
an analysis by George Weisz, 1 as a result of clinical researchers seeking to “permit rigorous …

Background REVEAL (The Registry to Evaluate Early and Long-term Pulmonary Arterial
Hypertension Disease Management) provides current demographics of patients with group …

Background. There are no Canadian prevalence studies on pulmonary arterial hypertension
(PAH) to date. We described the characteristics of treated PAH patients and the healthcare …

Background As with many uncommon diseases, data in patients with pulmonary arterial
hypertension are sparse in regard to emergency service visits, hospitalizations, and …

Pulmonary arterial hypertension (PAH) is an incurable, progressive disease of the
pulmonary vasculature that leads to right heart failure and, ultimately, death. Significant …

Objectives This study assessed pulmonary hypertension (PH)-related hospitalizations,
including readmissions, among US patients with pulmonary arterial hypertension (PAH), a …